A fiber-derived compound made by treating rice bran with mushroom enzymes that works on the immune system rather than attacking tumors directly. Its most reliable effect is rousing tumor-killing immune cells; small, preliminary studies suggest better well-being and possibly longer survival when added to standard cancer treatment. Well tolerated; best seen as a low-risk add-on, not a replacement. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Natural killer (NK) cell cytotoxic activity | Rising from baseline | Tracks the compound's primary proposed action |
| Complete blood count with white-cell differential | Lymphocytes ~20–40% of white cells; normal absolute counts | Gauges overall immune-cell numbers and marrow reserve |
| AST and ALT (liver enzymes) | Roughly <25 U/L (functional) | Confirms liver tolerability; relevant in liver cancer use |
| Fasting glucose / HbA1c | Fasting ~70–90 mg/dL; HbA1c <5.4% | Detects additive glucose lowering in diabetics |
| High-sensitivity C-reactive protein (CRP) | <1.0 mg/L | Tracks systemic inflammation, which immune modulation may shift |
| Total protein / albumin | Albumin ~4.0–5.0 g/dL | Reflects nutritional reserve linked to quality-of-life response |
| Tumor markers (e.g., PSA, CA 15-3, AFP as appropriate) | Cancer-specific; trend toward lower is favorable | Follows disease activity for the relevant cancer |
Cadence: Baseline before starting, then ~4–8 weeks after starting, then every 3–6 months during extended use; tumor markers timed to the oncologist's schedule.